A Preview Of Rigel Pharmaceuticals's Earnings
Earnings Preview: RIGL to Report Financial Results Post-market on May 06
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update
Express News | Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Benign Growth For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Underpins Stock's 26% Plummet
Express News | Rigel Announces Settlement Agreement Resolving Tavalisse® (Fostamatinib Disodium Hexahydrate) Patent Litigation
Rigel Announces Settlement Agreement Resolving TAVALISSE (Fostamatinib Disodium Hexahydrate) Patent Litigation
Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are
Rigel Pharmaceuticals' (NASDAQ:RIGL) Solid Earnings Are Supported By Other Strong Factors
Express News | Rigel Appoints Mark W. Frohlich, M.d. to Board of Directors
Press Release: Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Rigel Pharmaceuticals Price Target Raised to $55.00/Share From $49.00 by Citigroup
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Raises Target Price to $55
Express News | Rigel Pharmaceuticals Inc : Citigroup Raises Target Price to $55 From $49
Rigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor Appeal
Rigel Pharmaceuticals Shares Are Trading Lower. The Company Reported Q4 Financial Results.
B.Riley Financial Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Cuts Target Price to $24
B. Riley Raises Price Target on Rigel Pharmaceuticals to $24 From $20, Keeps Neutral Rating